BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32654796)

  • 21. Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival.
    Murphy S; Probert G; Anderson J; Pollock S; Taylor I; Clague H; Sridharan K
    Clin Oncol (R Coll Radiol); 2013 Dec; 25(12):713-8. PubMed ID: 24051173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
    Velcheti V; Hu X; Piperdi B; Burke T
    Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
    Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
    J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
    Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy.
    González García A; Sifuentes Giraldo WA; Grillo Fernández E; Zea Mendoza A
    J Clin Rheumatol; 2014 Dec; 20(8):449-50. PubMed ID: 25417687
    [No Abstract]   [Full Text] [Related]  

  • 26. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
    Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
    BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
    Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
    Miyazaki K; Satoh H; Tamura T
    Lung Cancer; 2016 Dec; 102():135. PubMed ID: 27526980
    [No Abstract]   [Full Text] [Related]  

  • 29. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
    Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
    J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study.
    Lou Y; Xu J; Zhang Y; Lu J; Chu T; Zhang X; Wang H; Zhong H; Zhang W; Han B
    Target Oncol; 2020 Apr; 15(2):175-184. PubMed ID: 32170554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
    J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
    Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
    Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
    Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE
    Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report.
    Sullivan K; Lee CS
    J Oncol Pharm Pract; 2019 Dec; 25(8):2007-2009. PubMed ID: 30501380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palm Pustules Induced by Pemetrexed.
    Nakashima K; Tsubata Y; Niihara H; Araki A; Isobe T
    J Thorac Oncol; 2021 Sep; 16(9):1589-1591. PubMed ID: 34242787
    [No Abstract]   [Full Text] [Related]  

  • 37. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
    Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
    JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
    Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
    Tamiya A; Tamiya M; Shiroyama T; Kanazu M; Hirooka A; Tsuji T; Morishita N; Asami K; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Hirashima T; Atagi S; Kawase I
    Ann Oncol; 2013 Apr; 24(4):980-5. PubMed ID: 23136232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.